On July 20th, 2022, the research article regarding nasal-spraying spore probiotics LiveSpo Navax entitled “Nasal-spraying Bacillus spores as an effective symptomatic treatment for children with acute respiratory syncytial virus infection” was published in Scientific Reports-Nature, the prestigious international scientific journal. The study was conducted in collaboration between LiveSpo Pharma Co. Ltd., and researchers at Vietnam National Children’s Hospital.
Scientific Reports, belonging to Nature system, is famous medical journal in the world. By the publication on effects of spore probiotics originating from Vietnam, Dr. Nguyen Hoa Anh – Director of ANABIO R&D Co. Ltd., expects to be able to contribute to the field of science and public health care, especially children.
The research group conducted the clinical trial of nasal-spraying spore probiotics LiveSpo Navax on RSV infected children. LiveSpo Navax is ear, nose and throat cleaning solution containing more than 5 billion of spore probiotics Bacillus subtilis and Bacillus clausii and physiological saline solution (NaCl 0.9%) in sufficient 5 mL. Product is dedicated for cleaning of ear, nose and throat; help preventing and reducing the risk of ear, nose and throat infections; supplementing of spore probiotics to protect and recover the nasal mucosa.
The study demonstrates that LiveSpo Navax treatment resulted in 1-day faster recovery time and 10-50% better efficacy in relieving typical symptoms of acute respiratory tract infections (ARTIs) in comparison to control group. At day 3 of treatment, levels of RSV load and pro-inflammatory cytokines in nasopharyngeal samples of patients using LiveSpo Navax were remarkably reduced by 630 folds and 2.7-12.7 folds, respectively, which was 53-fold and 1.8 to 3.6-fold more effective than those in standard of care treatment.
Spraying LiveSpo Navax directly in to nasal cavity helps reducing the symptoms of ARTIs rapidly. In combination between LiveSpo Navax and standard therapy, the recovery time is shortened by 1 day (17%) with 10-50% more effectiveness in relieving typical symptom of ARTIs than physiological saline solution. Most of patients having positive co-infection bacteria in Navax group became negative after 3 days of treatment, while low reduction and even increment in co-infection bacteria were detected in most of patients in standard of care treatment.
Dr, Nguyen Hoa Anh, a member of research group and Director of ANABIO R&D, said: The mechanism of interaction between spore probiotic Bacillus in LiveSpo Navax and virus and immune system of nasal mucosa is based on non-specific interaction. “Our discovery suggests that LiveSpo Navax may useful for against the recent novel respiratory viral variants such as nCoV. This novel supportive treatment method using probiotics has the advantage of simplicity of use, low cost, effectible and viral infected prevention. It can support the developing countries with limited health resources”.